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Abstract
Biofilm formation by pathogenic bacteria is a hallmark of chronic infections. In many cases, lectins 
play key roles in establishing biofilms. The pathogen Pseudomonas aeruginosa often exhibiting 
various drug resistances employs its lectins LecA and LecB as virulence factors and biofilm 
building blocks. Therefore, inhibition of the function of these proteins is thought to have potential in 
developing ‘pathoblockers’ preventing biofilm formation and virulence. Here, we describe for the 
first time a covalent lectin inhibitor specific to a carbohydrate binding site. In addition we report its 
application in the LecA-specific in vitro imaging of biofilms formed by P. aeruginosa.
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Lectins are carbohydrate-binding proteins with very diverse functions that are found in all domains 
of life.[1,2] These proteins play crucial roles in numerous processes such as cell-cell recognition, 
infection processes and immune defense. They are generally characterized by an intermediate to 
low affinity towards their carbohydrate ligands that is often overcome by Nature through 
multivalency of both the lectin receptors and their carbohydrate ligands resulting in avidity with an 
increase in apparent affinity.
Because these carbohydrate-binding proteins play essential roles in a number of pathological 
processes, they have become attractive targets for therapy. However, the fact that lectins display 
moderate affinities to their ligands renders this class of proteins as difficult targets for drugs.[3] 
Despite this drawback, a number of recent success stories impressively demonstrated their potential 
for therapy: the selectin antagonist GMI-1070 is currently in phase III clinical trials and various 
FimH inhibitors are in the late preclinical stage.[3-7]
Lectins are involved in infections with the Gram-negative bacterium P. aeruginosa, one important 
member of the often highly drug resistant ESKAPE pathogens which are Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, P. aeruginosa, and 
Enterobacter species and currently cause most of the severe hospital infections in western countries.
[8,9] The two bacterial lectins,[10] LecA and LecB, are virulence factors and important for bacterial 
adhesion and biofilm formation.[11,12] The latter is especially problematic as resistance against 
antibiotics inside a biofilm is increased by a factor of 10-1000.[13] Thus, the inhibition of these 
lectins provides a promising way to dismantle the bacterium from the protective biofilm 
environment and restore immune defense and activity of antibiotics.[14] Current approaches to 
inhibit both lectins range from small molecules to multivalent structures and are summarized in 
recent reviews.[15-19] We focus on the development of small molecules and recently published 
various potent glycomimetic inhibitors for the high affinity lectin LecB as inhibitors of P. 
aeruginosa adhesion.[20-25] In contrast, LecA only has an intermediate affinity for its monovalent D-
galactose-derived ligands in the 50-100 µM range.[10,26,27] Phenyl β-D-galactosides and derivatives 
showed an increased affinity of approx. 10 µM, e.g. compound 1 (Fig. 1), but despite a high number 
of derivatives analyzed, no further significant increase in potency could be achieved.[28-31]
Covalent inhibition is one strategy to avoid dissociation of the inhibitor from the target and thus to 
persistently inactivate proteins. To date, a specific covalent inhibition of the carbohydrate binding 
site in a lectin has not been achieved despite attempts using squaric acid to target FimH[32] or 
photoactivatable substituents for the targeting of galectins.[33-35] The latter probes covalently bind to 
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unspecific residues of the protein in proximity (3 Å) to the photoactivated center. The crystal 
structure of LecA[26,36] reveals the presence of one cysteine residue (Cys62) in the carbohydrate 
binding domain (Figure 1). The specific targeting of cysteine residues with electrophilic warheads is 
a general strategy in the search for cysteine protease inhibitors,[37] but has never been addressed in 
carbohydrate recognition domains. In order to target Cys62, we designed the two diastereoisomeric 
galactose-derived epoxides 2 and 3 (Figure 1) as potential covalent active site inhibitors of LecA.
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Figure 1: A. Galactoside recognition by the bacterial lectin LecA (pdb: 3ZYF[36]); B. Electrophilic epoxide derivatives 
2 and 3 for the targeting of Cys62. The distances from Cys62-S to C6 and O6 of 1 are between 4.1 and 4.3 Å. (sc = side 
chain, bb = back bone)
3
HO
O
HO
HO
OH
OH
O
O
O
O
OH
O
O
O
O
O
O
O
O
O
O
O
CH2
O
AcO
O
AcO
AcO
CH2
OAc
AcO
O
AcO
AcO
CH2
O
(vii) (viii)
(i) (ii) (iii) (iv)-(v)
4 5, 66% 6, 70% 7 8, 33% (3 steps)
9, 56%
8
10, 97%
2, 9%
3, 19%
(vi)
HO
O
O
HO
HO
O
HO
O
O
HO
HO
O
HO
O
HO
HO
CH2
O
IC50 > 3 mM
IC50 > 3 mM
IC50 = 64 ± 42 µM
Scheme 1: Synthesis of LecA-directed epoxides and competitive binding IC50 values for LecA. (i) acetone, ZnCl2, 
H2SO4; (ii) (COCl)2, DMSO, NEt3, CH2Cl2, -78 °C to 0 °C; (iii) PPh3*MeI, NaH, DMSO; (iv) 70% HOAc aq.; (v) 
Ac2O, pyridine; (vi) PhOH, BF3*Et2O, CH2Cl2, -20 °C - r.t.; (vii)  NaOMe, MeOH, r.t.; (viii) mCPBA, NaHCO3, 
CH2Cl2/MeOH;
The 8 step synthesis of epoxides 2 and 3 started from D-galactose (4) with epoxidation as the last 
step (Scheme 1). 4 was protected as diacetonide (→5) and the free primary hydroxyl group was 
oxidized under Swern conditions (→6) in good yields. Then, heptose 7 was established in a Wittig 
reaction followed by a change in protecting groups from acetonides to acetates (→8). Lewis acid 
catalyzed glycosylation of phenol with 8 gave phenyl β-glycoside 9 in good yield. 9 was 
deprotected in a Zemplén transesterification reaction to give olefin 10 in 97% yield. Late stage 
oxidation with mCPBA yielded the two diasteroisomeric epoxides 2 and 3 in 9% and 19%, 
respectively. The stereochemistry of 3 was established by X-ray crystallography in complex with 
LecA (see Figure 3).
Both epoxides 2 and 3 and olefin 10 were then tested in a recently developed competitive binding 
assay[31] for inhibition of LecA. No inhibition was observed for olefin 10 up to 3 mM. In contrast, 
the epoxides showed a strong diastereoselectivity for inhibition of LecA: 3 was a good inhibitor 
with an IC50 = 64 µM, whereas its diastereomer 2 was not recognized (IC50 > 3 mM), indicating a 
specific binding of epoxide 3 to LecA.
To assess the binding mode of 3 with LecA, we analyzed LecA in presence and absence of 3 by 
mass spectrometry (Figure 2). LC-MS measurements on intact protein level showed a mass shift of 
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268.1 Da when incubated with 3 and thus prove a covalent binding of the epoxide to LecA (Figure 
2A, B). In order to localize the binding site of the epoxide, an MS based sequencing using MALDI 
in source decay (ISD) was performed for both samples (Figure 2C). MALDI-ISD experiments with 
c-ion series annotated in a range from 5000 to 8000 m/z were instrumental to identify the peptide 
sequence ranging from Arg48 to Thr74 and Asn71, respectively. For the LecA sample co-incubated 
with 3, a mass increase of 268 Da to the c62 ion indicated the binding of compound 3 to Cys62 of 
LecA. Thus, 3 showed covalent binding to LecA and the nucleophile for the epoxide ring opening 
was the sulfhydryl group of Cys62 in the carbohydrate recognition domain.
Figure 2: Covalent binding mode of 3 with LecA established by mass spectrometry. Deconvoluted intact protein MS 
spectra of LecA without inhibitor (A) and with inhibitor 3 (B). (C) MALDI-ISD experiments with c-ion series annotated 
in a range from 5000 to 8000 m/z.
We then crystallized LecA in complex with epoxide 3 and solved the structure by X-ray 
crystallography (Figure 3). In this complex, 3 adopts a coordination to the calcium ion bound to 
LecA as it had been reported for other galactosides before.[26,36] Surprisingly, despite its orientation 
towards Cys62 the epoxide moiety in 3 is still intact and the covalent adduct could not be observed 
in this structure. These differences to the covalent adduct observed by mass spectrometry are likely 
a result of the different pH values of the buffers employed: lectin binding assays and mass 
spectrometry were performed at a physiologically buffered pH (7.4), whereas LecA is crystallized at 
pH 4.6. Numerous attempts to obtain LecA crystals with 3 as a covalent adduct by cocrystallization 
or soaking at neutral pH have been unsuccessful to date. All data collection of protein crystals 
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incubated with diastereomeric epoxide 2 led to empty binding sites confirming the low affinity of 2 
for LecA. 
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Figure 3: Crystal structure of epoxide 3 in complex with LecA at 1.80 Å resolution in the non-covalent binding mode 
obtained at pH 4.6 (pdb code 5MIH). A. Electron density displayed at 1σ  for ligand and Cys62 side chain. B. Interaction 
of the ligand with LecA: the epoxy-oxygen atom accepts hydrogen bonds from His50 and one protein-bound water 
molecule. In addition, His50 established a CH-π interaction with the phenyl agylycon. In the crystal, the sulfur atom of 
Cys62 is 3.3 Å away from C7 of ligand 3.
In order to exploit this unique covalent lectin ligand for biological applications such as lectin 
specific staining, we synthesized alkyne-bearing derivatives that were then coupled to a fluorescent 
azide in a Huisgen dipolar cycloaddition (Scheme 2). Glycosyl donor 8 was reacted under Lewis 
acid catalysis with the acceptor monopropargyl hydroquinone to give the glycoside 11. Here, we 
first oxidized the peracetylated olefin 11 using mCPBA and the two diasteromeric epoxides 12 and 
13 were obtained after chromatographic separation in 21% and 46% yield, respectively. 
Subsequently, the acetates were removed in a Zemplén type reaction to individually give the 14 or 
15. Both were then tested for inhibition of LecA showing a comparable diastereoselectivity as 
observed for the unsubstituted phenyl derivatives 2 and 3 before: 6D epoxide 15 inhibited LecA 
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with an IC50 of 109 µM, whereas the diastereomeric 6L epoxide 14 was inactive (IC50 > 3 mM). The 
stereochemistry of 14 and 15 was unambiguously assigned by combining the activity data and 
NMR chemical shift and coupling constant analysis and comparison with analogs 2 and 3. The 
active diasteromer 15 was then coupled in a copper(II)-catalyzed click reaction to the azide 16[38] to 
give fluorescent probe 17 in good yields.
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Scheme 2: Synthesis of LecA-directed propargylated epoxides with LecA inhibition data and synthesis of fluorescent 
derivative 17. (i) hydoquinone monopropargyl ether, BF3*Et2O, CH2Cl2, -20 °C - r.t.; (ii)  mCPBA, NaHCO3, CH2Cl2, 0 
°C - r.t.; (iii) NaOMe, MeOH, 0 °C; (iv) CuSO4, sodium ascorbate, H2O, DMF, r.t.; 
Tools to visualize the presence of carbapenem-resistant bacterial pathogens in a test tube by specific 
activity-based probes have recently been reported.[39] The visualization of bacterial biofilm 
structures is of outstanding current interest, both, in vitro and in vivo.[40-42] LecA is involved in the 
biofilm formation of P. aeruginosa and LecA-deficient strains were shown to have thinner biofilms 
with a reduced biomass.[12,43] Because the expression of LecA is upregulated in biofilms and it is 
located extracellularly,[12,44,45] this protein is a promising target for the imaging of biofilms. We 
therefore explored whether the LecA-directed epoxides reported here can specifically stain biofilms 
of P. aeruginosa. Bacterial biofilms were grown using mCherry-expressing PAO1 wildtype bacteria 
and the corresponding LecA-deficient strain PAO1 ∆lecA and then analyzed by confocal 
fluorescence microscopy (Figures 4, 5). Under shaking growth conditions, bacterial aggregates[46] of 
the biofilm were observed in the PAO1 wildtype strain, whereas the ∆lecA strain generally showed 
a heavily reduced number of aggregates with smaller sizes and therefore also a higher number of 
planktonic bacteria since bacterial growth is comparable (Figures 4, 5, S21). After addition of the 
LecA-directed dye 17 to the bacterial cultures, a specific staining of the wildtype biofilm aggregates 
was observed and no staining was visible in case of the aggregates formed by the ∆lecA strain. The 
green fluorescence originating from 17 was observed on the entire structure of the wildtype 
bacterial aggregates, whereas no or only a very faint color on the surface of the ∆lecA strain 
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aggregates was observed without any detectable fluorophore inside these aggregates. The largest 
aggregate found for the ∆lecA strain was also analyzed (Figures S22-S24) and staining was LecA-
specific and independent of aggregate size. Thus, the bacterial lectin LecA can be exploited as a 
target to visualize biofilms of P. aeruginosa using conjugates of LecA-ligands, such as the 
galactose-derived epoxide 17.
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Figure 4: Galleries of LecA-dependent staining of P. aeruginosa biofilms with 17. P. aeruginosa PAO1 wt (A) or the 
lecA knockout (∆lecA) mutant (B) expressing mCherry from pMP7605 were incubated at 37 °C for 24 hours with 
agitation (180 rpm). Biofilms were stained with the covalent LecA ligand fused to fluorescein (17) for 10 - 30 min. Z-
stacks (232 x 232 µm) were recorded every 2 µm at 561 nm for mCherry (red, A and B, upper panels)  and 488 nm for 
fluorescein (green, A and B middle panels). The galleries show every 4th z-stack recorded. Lower panels show merged 
images of both channels (488 nm and 561 nm).
A B
Figure 5: Three-dimensional imaging of LecA-dependent staining of P. aeruginosa PAO1 biofilms with 17. P. 
aeruginosa PAO1 wt (A) or the lecA knockout (∆lecA)  mutant (B) expressing mCherry from pMP7605 were incubated 
at 37 °C for 24 hours with agitation (180 rpm). Biofilms were stained with 17 for 10 - 30 min. Z-stacks (232 x 232 µm) 
were recorded   every 2 µm at 561 nm for mCherry (red)  and 488 nm for fluorescein (green). The 3D images show 
merged images of both channels (488 nm and 561 nm) from top and side views.
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In summary, we have developed the first covalent inhibitor of carbohydrate binding sites by rational 
structure-based design. Both diastereomers of the epoxygalactoheptoside 2 and 3 were synthesized 
and biologically evaluated. LecA displayed a strong diastereoselectivity for the 6D epimer 3 over its 
6L isomer 2. The binding site and its covalent nature at physiological pH was established using 
mass spectrometry-based sequencing and the non-covalent crystal structure of 3 in complex with 
LecA was solved at pH 4.6. Finally, we used the fluoresceine-derivative 17 for the LecA-specific 
staining of P. aeruginosa biofilms. Such conjugates may lead to the development of pathogen-
specific imaging agents to localize bacterial biofilm-associated infections inside an infected host 
enabling pathogen- and tissue-directed therapy.
Acknowledgements
The authors acknowledge the continuous support of Prof. Rolf W. Hartmann (HIPS). We are further 
grateful to Prof. Bodo Philipp (University of Münster) and Prof. Arthur F. J. Ram (Leiden 
University) for providing bacterial strains and plasmids used in this study, to MSc. Sarah Henrikus 
(Saarland University) for the synthesis of 16 and to MSc. Laura Becker (University of Konstanz) 
for initial synthetic experiments towards the galactose-derived epoxides and Dr. Josef Zapp 
(Saarland University) for acquisition of NMR spectra. Emilie Gillon prepared LecA for 
crystallization and performed some crystallization trials. A.V. acknowledges financial support from 
the European Community's Seventh Framework Programme (FP7/2007-2013) under BioStruct-X 
(grant agreement N°283570). The authors thank the EMBL-Grenoble staff for assistance in using 
the High Throughput Crystallisation (HTX) facility and the European Synchrotron Radiation 
Facility, Grenoble, France for the access and technical support to beamline BM30A-FIP. A.T. 
acknowledges the following funding agencies for generous funding: the Helmholtz-Association 
(grant no. VH-NG-934), the Deutsche Forschungsgemeinschaft (grant no. Ti 756/2-1) and the 
European Research Council for an ERC Starting Grant (SWEETBULLETS).
Author contributions
S.W. performed and analyzed microbiology and biofilm experiments, D.H. performed all chemical 
syntheses except for compound 17 which was synthesized by R.S., I.J. and R.S. performed the 
competitive LecA inhibition assays, M.H. and R.M. performed and analyzed protein MS and small 
molecule HRMS experiments, A.V. and A.I. determined the crystal structure of 3 in complex with 
LecA, A.T. conceived and designed the study, A.T. wrote the paper with input from all authors.
9
Experimental
General Experimental Details
Commercial chemicals and solvents were used without further purification. D-galactose was 
purchased from Dextra Laboratories (Reading, UK) and fluorescein isothiocyanate isomer I (FITC) 
from Sigma-Aldrich (Munich, Germany). Deuterated solvents were from Eurisotop (Saarbrücken, 
Germany). Thin layer chromatography (TLC) was performed using silica gel 60 coated aluminum 
sheets containing fluorescence indicator (Macherey & Nagel, Düren, Germany) using UV light (254 
nm) and by charring either in aqueous KMnO4 solution or in a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 
10% H2SO4) with heating. Medium pressure liquid chromatography (MPLC) was performed on a 
Teledyne Isco Combiflash Rf200 system using pre-packed silica gel 60 columns from Teledyne 
Isco, SiliCycle or Macherey-Nagel. Nuclear magnetic resonance (NMR) spectroscopy was 
performed on a Bruker Avance III 500 UltraShield spectrometer at 500 MHz (1H) or 126 MHz 
(13C). Chemical shifts are given in ppm and were calibrated on residual solvent peaks.[47] 
Multiplicities were specified as s (singlet), m (multiplet) or interpreted according to 1st order and 
higher order where possible. The signals were assigned with the help of 1H,1H-COSY, DEPT-135-
edited 1H,13C-HSQC and 1H,13C-HMBC experiments. Preparative HPLC-MS was performed on a 
Thermo Dionex Ultimate 3000 HPLC with UV detection. Analytical HPLC-MS was performed on 
a Thermo Dionex Ultimate 3000 HPLC coupled to a Bruker amaZon SL for low resolution mass 
spectra or on a Bruker maxis 4G hr-QqToF spectrometer for high resolution, and the data were 
analyzed using DataAnalysis (Bruker Daltonics, Bremen, Germany). 
1,2:3,4-Di-O-isopropylidene-α-D-galacto-hexodialdo-1,5-pyranose (6). 6 was synthesized from 
1,2:3,4-Di-O-isopropylidene-α-D-galactopyranose[48] (5, 500 mg, 1.92 mmol) by Swern oxidation 
following the procedure by Streicher and Wünsch.[49] After chromatography, 6 (348 mg, 1.35 mmol) 
was obtained as colorless amorphous solid. The NMR of 6 corresponded to the one given in the 
literature.[50]
6,7-Dideoxy-1,2:3,4-di-O-isopropylidene-α-D-galacto-hept-6-enopyranose (7). 7 was synthesized 
by treating 6 with a Wittig reagent in analogy to Lehmann and Schäfer.[51] In contrast to the 
literature, we used methyltriphenylphosphonium iodide and sodium hydride in DMSO to generate 
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the ylid. Crude olefin 7 was obtained after extraction and was used without purification in the next 
step. The NMR of the crude product corresponded to literature values.[50]
6,7-Dideoxy-1,2,3,4-tetra-O-acetyl-α/β-D-galacto-hept-6-enopyranose (8). α-8 was first described 
by Lee et al. and the NMR corresponded to literature values.[50]
Phenyl 2,3,4-tri-O-acetyl-6,7-dideoxy-β-D-galacto-hept-6-enopyranoside (9).
8 (1.24 g, 3.6 mmol) and phenol (678 mg, 7.2 mmol) were dissolved in dry CH2Cl2 (24 mL) and 
added to a round bottom flask with powdered activated molecular sieves (3Å, 600 mg) under argon. 
After cooling to 0 °C, BF3•Et2O (1.77 mL, 14.4 mmol) was added in four portions over 1 h. Then, 
the reaction was stirred for 50 min at 0 °C after which the reaction was allowed to warm to r.t. 
during 20 min. The reaction was stopped by pouring on cold aqueous satd. NaHCO3, after addition 
of CH2Cl2 (60 mL) the phases were separated and the organic layer was washed with cold aqueous 
satd. NaHCO3 (2 x 60 mL). The combined aqueous layers were extracted with CH2Cl2 (3 x 60 mL). 
The combined organic layers were dried over anhydrous Na2SO4, filtered and the volatiles were 
removed in vacuo. The residue was purified by MPLC (SiO2, petrol ether/EtOAc gradient of 
5-50%) to elute first the anomer α-9 (55 mg, 4%), then the title compound 9 (760 mg, 56%) and 
then recovered starting material 8 (358 mg, 26%). Analytical data for 9: 1H NMR (400 MHz, 
CHCl3-d1) δ 7.34 – 7.25 (m, 2H, ArH), 7.10 – 6.99 (m, 3H, ArH), 5.76 (ddd, J = 17.3, 10.7, 4.8 Hz, 
1H, H6), 5.51 (dd, J = 10.5, 8.0 Hz, 1H, H2), 5.46 – 5.37 (m, 2H, H4, H7a), 5.27 (dt, J = 10.7, 1.4 
Hz, 1H, H7b), 5.15 (dd, J = 10.4, 3.4 Hz, 1H, H3), 5.08 (d, J = 7.9 Hz, 1H, H1), 4.33 (dq, J = 4.7, 
1.5 Hz, 1H, H5), 2.14 (s, 3H, CH3CO), 2.06 (s, 3H, CH3CO), 2.01 (s, 3H, CH3CO). 13C NMR (101 
MHz, CHCl3-d1) δ 170.56 (CO), 170.30 (CO), 169.56 (CO), 157.30 (ArC), 131.67 (C6), 129.69 
(2C, ArCH), 123.30 (ArCH), 118.58 (C7), 117.14 (2C, ArCH), 99.91 (C1), 73.93 (C5), 71.19 (C3), 
69.47 (C4), 68.91 (C2), 20.87 (CH3CO), 20.79 (CH3CO), 20.75 (CH3CO). LC-HRMS: 
[C19H22O8+Na]+ calcd: 401.1207, found: 401.1206.
Phenyl 6,7-dideoxy-β-D-galacto-hept-6-enopyranoside (10). Triacetate 9 (300 mg, 0.79 mmol) 
was dissolved in dry MeOH (8 mL) under nitrogen. A solution of NaOMe in MeOH (1M, 0.24 mL) 
was added and the reaction was stirred at r.t. for 2 h. The reaction was neutralized with acidic anion 
exchange resin (Amberlite IR120/H+), filtered and the volatiles were removed in vacuo. 10 (199 
mg, 97%) was obtained as analytically pure colorless amorphous solid. 1H NMR (500 MHz, 
MeOH-d4) δ 7.31 – 7.23 (m, 2H, ArH), 7.10 – 7.05 (m, 2H, ArH), 7.00 (tt, J = 7.4, 1.1 Hz, 1H, 
ArH), 5.98 (ddd, J = 17.4, 10.7, 5.5 Hz, 1H, H6), 5.37 (dt, J = 17.3, 1.7 Hz, 1H, H7a), 5.23 (dt, J = 
10.7, 1.6 Hz, 1H, H7b), 4.90 (d, J = 7.7 Hz, 1H, H1), 4.20 (dq, J = 5.5, 1.4 Hz, 1H, H5), 3.85 – 3.76 
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(m, 2H, H4, H2), 3.63 (dd, J = 9.7, 3.4 Hz, 1H, H3). 13C NMR (126 MHz, MeOH-d4) δ 159.18 
(ArC), 135.82 (C6), 130.33 (2C, ArCH), 123.34 (ArCH), 117.83 (2C, ArCH), 117.34 (C7), 102.78 
(C1), 76.99 (C5), 74.82 (C3), 72.76 (C4), 72.07 (C2). LC-HRMS: [C13H16O5+HCOO]- calcd: 
297.0980, found: 297.0977. 
Phenyl 6,7-dideoxy-6,7-epoxy-β-D-galacto-heptopyranoside (6L)-2 and (6D)-3
Olefin 10 (55 mg, 0.22 mmol) was dissolved in dry CH2Cl2 (6 mL) containing 3% MeOH and 
NaHCO3 (80 mg, 0.95 mmol) was added. After cooling to 0 °C, mCPBA (135 mg, 0.78 mmol) was 
added portionwise under stirring. Stirring was continued for 10 min and the reaction was allowed to 
warm to r.t.. After 3 d, mCPBA (135 mg, 0.78 mmol) and NaHCO3 (80 mg, 0.95 mmol) was added. 
After a reaction time of 10 d, the reaction was diluted with EtOAc (25 mL) and washed with brine 
(2 x 3 mL). The organic layer was dried over Na2SO4, filtered and the volatiles were removed in 
vacuo. The aqueous phase contained the desired products and was therefore lyophilized and the 
combined residues were purified by normal phase flash chromatography to give impure 19 mg of 3 
and 17 mg of 2. Both were then separately purified by reversed phase (C18) flash chromatography 
to give 2 (5.0 mg, 9%) and its epimer 3 (11.0 mg, 19%). The stereochemistry of 2 and 3 was 
assigned by co-crystallization of the active diastereomer 3 with LecA (vide infra). Analytical data 
for (6L)-2: (DH174-Fr1(„Prod.B“)): 1H NMR (500 MHz, MeOH-d4) δ 7.32 – 7.25 (m, 2H, ArH), 
7.13 – 7.07 (m, 2H, ArH), 7.00 (tt, J = 7.5, 1.1 Hz, 1H, ArH), 4.83 (d, J = 7.8 Hz, 1H, H1, signal 
overlap with residual water), 3.93 (dd, J = 3.4, 1.1 Hz, 1H, H4), 3.82 (dd, J = 9.8, 7.7 Hz, 1H, H2), 
3.56 (dd, J = 9.7, 3.4 Hz, 1H, H3), 3.35 – 3.29 (m, 1H, H6, signal overlap with residual solvent), 
3.27 (dd, J = 6.7, 1.2 Hz, 1H, H5), 2.83 (dd, J = 4.9, 4.2 Hz, 1H, H7a), 2.71 (dd, J = 5.0, 2.7 Hz, 
1H, H7b). 13C NMR (126 MHz, MeOH-d4) δ 159.19 (ArC), 130.38 (2C, ArCH), 123.39 (ArCH), 
117.82 (2C, ArCH), 102.81 (C1), 78.79 (C5), 74.49 (C3), 72.06 (C2), 71.48 (C4), 52.89 (C6), 44.42 
(C7). LC-HRMS: [C13H16O2+HCOO]- calcd: 313.0929, found: 313.0928. Analytical data for 
(6D)-3: (DH174 Fr2(„Prod.A“)): 1H NMR (500 MHz, MeOH-d4) δ 7.32 – 7.22 (m, 2H, ArH), 7.08 
– 7.03 (m, 2H, ArH), 7.00 (tt, J = 7.4, 1.1 Hz, 1H, ArH), 4.85 – 4.83 (m, 1H, H1, signal overlap 
with residual water), 3.98 (dd, J = 3.4, 1.1 Hz, 1H, H4), 3.81 (dd, J = 9.8, 7.7 Hz, 1H, H2), 3.58 
(dd, J = 9.8, 3.4 Hz, 1H, H3), 3.44 (dd, J = 5.5, 1.2 Hz, 1H, H5), 3.26 (ddd, J = 5.4, 3.8, 2.7 Hz, 1H, 
H6), 2.88 – 2.79 (m, 2H, H7a,b). 13C NMR (126 MHz, MeOH-d4) δ 159.11 (ArC), 130.37 (2C, 
ArCH), 123.39 (ArCH), 117.80 (2C, ArCH), 102.79 (C1), 76.33 (C5), 74.55 (C3), 72.12 (C2), 
70.73 (C4), 51.32 (C6), 46.70 (C7). LC-HRMS: [C13H16O2+HCOO]- calcd: 313.0929, found: 
313.0930.
p-Propargyloxyphenyl 2,3,4-tri-O-acetyl-6,7-dideoxy-β-D-galacto-hept-6-enopyranoside 11. 11 
12
was prepared from 8 (800 mg, 2.32 mmol) and hydroquinone monopropargyl ether[52] (688 mg, 
4.64 mmol) as described for 9. Purification of the crude product yielded 11 (627 mg, 62%) as an oil 
and small amounts of its α-anomer and recovered α-8. Analytical data for 11: 1H NMR (500 MHz, 
CHCl3-d1) δ 7.03 – 6.95 (m, 2H, ArH), 6.95 – 6.86 (m, 2H, ArH), 5.76 (ddd, J = 17.2, 10.7, 4.8 Hz, 
1H, H6), 5.48 (dd, J = 10.5, 8.0 Hz, 1H, H2), 5.45 – 5.39 (m, 2H, H7a, H4), 5.28 (dt, J = 10.8, 1.3 
Hz, 1H, H7b), 5.13 (dd, J = 10.5, 3.4 Hz, 1H, H3), 4.97 (d, J = 8.0 Hz, 1H, H1), 4.64 (d, J = 2.4 Hz, 
2H, HCCCH2-OR), 4.29 (dq, J = 4.6, 1.4 Hz, 1H, H5), 2.51 (t, J = 2.4 Hz, 1H, HCCCH2-OR), 2.15 
(s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 2.01 (s, 3H, CH3CO); 13C NMR (126 MHz, CHCl3-d1) δ 
170.59 (CO), 170.33 (CO), 169.58 (CO), 153.65 (ArC), 152.01 (ArC), 131.69 (C6), 118.66 (2C, 
ArCH), 118.57 (C7), 115.99 (2C, ArCH), 100.84 (C1), 78.72 (HCCCH2-OR), 75.64 (HCCCH2-
OR), 73.89 (C5), 71.18 (C3), 69.46 (C4), 68.93 (C2), 56.45 (HCCCH2-OR), 20.92 (CH3CO), 20.82 
(CH3CO), 20.77 (CH3CO); LC-HRMS: [C22H24NaO9]+ calcd: 455.1313, found: 455.1309.
p-Propargyloxyphenyl 2,3,4-tri-O-acetyl-6,7-dideoxy-6,7-epoxy-β-D-galacto-heptopyranoside 
(6L)-12 and (6D)-13. 
 Olefin 11 (256 mg, 0.59 mmol) was dissolved in CH2Cl2 (12 mL) and cooled to 0 °C. mCPBA (511 
mg, 2.96 mmol) was added portionwise under stirring and cooling. Then, the reaction was allowed 
to warm to r.t. and stirring was continued for 6 d when the reaction was diluted with CH2Cl2 (60 
mL) and extracted with satd aq. Na2S2O3, NaHCO3, H2O. The organic layer was dried over Na2SO4, 
filtered and the volatiles were removed in vacuo. The residue was purified by MPLC (silica, PhMe/
EtOAc 5-15%) to give first 13 (119 mg, 46%) and then 12 (55 mg, 21%). Analytical data for 
(6D)-13: 1H NMR (500 MHz, CHCl3-d1) δ 7.00 – 6.83 (m, 4H, ArH), 5.55 (dd, 1H, J = 3.4, 1.0 Hz, 
H4), 5.46 (dd, J = 10.5, 7.9 Hz, 1H, H2), 5.09 (dd, J = 10.4, 3.4 Hz, 1H, H3), 4.90 (d, J = 7.9 Hz, 
1H, H1), 4.64 (d, J = 2.4 Hz, 2H, HCCCH2-OR), 3.64 (dd, J = 4.7, 1.2 Hz, 1H, H5), 3.10 (ddd, J = 
4.7, 3.7, 2.7 Hz, 1H, H6), 2.83 (dd, 1H, J = 5.3, 2.6 Hz, H7a), 2.81 (dd, 1H, J = 5.2, 3.8 Hz, H7b), 
2.51 (t, J = 2.4 Hz, 1H, HCCCH2-OR), 2.19 (s, 3H, CH3CO), 2.07 (s, 3H, CH3CO), 2.02 (s, 3H, 
CH3CO); 13C NMR (126 MHz, CHCl3-d1) δ 170.30 (CO), 170.20 (CO), 169.53 (CO), 153.74 
(ArC), 151.88 (ArC), 118.53 (2C, ArCH), 116.08 (2C, ArCH), 100.83 (C1), 78.70 (HCCCH2-OR), 
75.67 (HCCCH2-OR), 73.07 (C5), 70.85 (C3), 68.89 (C2), 68.02 (C4), 56.47 (HCCCH2-OR), 49.71 
(C6), 45.51 (C7), 20.88 (CH3CO), 20.83 (CH3CO), 20.74 (CH3CO). LC-HRMS: [C22H25O10]+ 
calcd: 449.1442, found: 449.1447. Analytical data for (6L)-12: 1H NMR (500 MHz, CHCl3-d1) δ 
7.01 – 6.97 (m, 2H, ArH), 6.94 – 6.89 (m, 2H, ArH), 5.53 – 5.45 (m, 2H, H2+H4), 5.05 (dd, J = 
10.4, 3.5 Hz, 1H, H3), 4.92 (d, J = 7.9 Hz, 1H, H1), 4.65 (d, J = 2.4 Hz, 2H, HCCCH2-OR), 3.43 
(dd, J = 5.9, 1.2 Hz, 1H, H5), 3.16 (ddd, J = 5.9, 4.2, 2.6 Hz, 1H, H6), 2.80 (dd, J = 4.6, 4.3 Hz, 1H, 
H7a), 2.66 (dd, J = 4.7, 2.7 Hz, 1H, H7b), 2.51 (t, J = 2.4 Hz, 1H, HCCCH2-OR), 2.21 (s, 3H, 
13
CH3CO), 2.08 (s, 3H, CH3CO), 2.02 (s, 3H, CH3CO); 13C NMR (126 MHz, CHCl3-d1) δ 170.53 
(CO), 170.27 (CO), 169.50 (CO), 153.73 (ArC), 151.93 (ArC), 118.57 (2C, ArCH), 116.10 (2C, 
ArCH), 100.76 (C1), 78.72 (HCCCH2-OR), 75.66 (HCCCH2-OR), 75.35 (C5), 70.86 (C3), 68.76 
(C2+C4), 56.50 (HCCCH2-OR), 50.89 (C6), 43.57 (C7), 20.89 (2C, CH3CO), 20.74 (CH3CO); LC-
HRMS: [C22H25O10]+ calcd: 449.1442, found: 449.1439. 
p-Propargyloxyphenyl 6,7-dideoxy-6,7-epoxy-β-D-galacto-heptopyranoside (6L)-14.
Acetylated (6L)-12 (34 mg, 76 µmol) was dissolved in dry MeOH (380 µL) and cooled to 0 °C. 
Freshly prepared NaOMe (60 mM in MeOH, 570 µL) was added dropwise and the reaction was 
stirred for 1.5 h at 0 °C. Then, Amberlite IR120/H+ was added, the reaction was filtered and the 
volatiles were removed in vacuo. Analytically pure (6L)-14 (21 mg, 86%) was obtained. 1H NMR 
(500 MHz, MeOH-d4) δ 7.06 (d, J = 9.2 Hz, 2H, ArH), 6.91 (d, J = 9.1 Hz, 2H, ArH), 4.72 (d, J = 
7.8 Hz, 1H, H1), 4.67 (d, J = 2.4 Hz, 2H, HCCCH2-OR), 3.91 (dd, J = 3.5, 1.1 Hz, 1H, H4), 3.79 
(dd, J = 9.8, 7.7 Hz, 1H, H2), 3.54 (dd, J = 9.8, 3.4 Hz, 1H, H3), 3.33 – 3.29 (m, 1H, H6), 3.23 (dd, 
J = 6.7, 1.2 Hz, 1H, H5), 2.91 (t, J = 2.4 Hz, 1H, HCCCH2-OR), 2.83 (dd, J = 4.9, 4.2 Hz, 1H, 
H7a), 2.70 (dd, J = 4.9, 2.7 Hz, 1H, H7b); 13C NMR (126 MHz, MeOH-d4) δ 154.58 (ArC), 153.83 
(ArC), 119.12 (2C, ArCH), 116.86 (2C, ArCH), 103.79 (C1), 79.99 (HCCCH2-OR), 78.74 (C5), 
76.54 (HCCCH2-OR), 74.47 (C3,) 72.08 (C2), 71.47 (C4), 57.19 (HCCCH2-OR), 52.92 (C6), 44.44 
(C7); LC-HRMS: [C16H18O7+HCOO]- calcd: 367.1035, found: 367.1031.
p-Propargyloxyphenyl 6,7-dideoxy-6,7-epoxy-β-D-galacto-heptopyranoside (6D)-15.
Acetylated (6L)-13 (70 mg, 156 µmol) was was treated with NaOMe as described before for its 
diastereomer. Analytically pure (6D)-15 (47 mg, 94%) was obtained. 1H NMR (500 MHz, MeOH-
d4) δ 7.04 – 6.99 (m, 2H, ArH), 6.96 – 6.87 (m, 2H, ArH), 4.72 (d, J = 7.7 Hz, 1H, H1), 4.67 (d, J = 
2.5 Hz, 2H, HCCCH2-OR), 3.96 (dd, J = 3.4, 1.2 Hz, 1H, H4), 3.78 (dd, J = 9.8, 7.7 Hz, 1H, H2), 
3.57 (dd, J = 9.8, 3.5 Hz, 1H, H3), 3.40 (dd, J = 5.4, 1.1 Hz, 1H, H5), 3.26 (ddd, J = 5.4, 3.9, 2.6 
Hz, 1H, H6), 2.91 (t, J = 2.4 Hz, 1H, HCCCH2-OR), 2.84 (dd, J = 5.3, 3.9 Hz, 1H, H7a), 2.81 (dd, J 
= 5.3, 2.7 Hz, 1H, H7b); 13C NMR (126 MHz, MeOH-d4) δ 154.58 (ArC), 153.73 (ArC), 119.14 
(2C, ArCH), 116.84 (2C, ArCH), 103.80 (C1), 79.99 (HCCCH2-OR), 76.55 (C5), 76.26 (HCCCH2-
OR), 74.52 (C3), 72.15 (C2), 70.71 (C4), 57.18 (HCCCH2-OR), 51.35 (C6), 46.71 (C7); LC-
HRMS: [C16H18O7+HCOO]- calcd: 367.1035, found: 367.1033. 
Fluoresceine coupled 6,7-dideoxy-6,7-epoxy-β-D-galacto-heptopyranoside (6D)-17.
Propargylated epoxide (6D)-15 (1.28 mg, 4 µmol) and azide modified FITC 16[38] (2.8 mg, 4 µmol) 
were dissolved in DMF (120 µL). After the addition of CuSO4*5H2O (0.3 mg, 1.2 µmol) and 
14
sodium ascorbate (80 µL, 100 mM in H2O, 8 µmol), the reaction was stirred at r.t. for 3 h. After 
lyophilization, the residue was purified by preparative HPLC (C18, H2O/MeCN, gradient of 
20-60%) to give pure (6D)-17 (2.8 mg, 76%). LC-MS: [C45H48N5O15S]+ calcd: 930.3, found: 930.3. 
Competitive binding to LecA using fluorescence polarization
The protein LecA was expressed and purified as described previously.[27,31] The competitive binding 
assay was performed as described previously.[31] In brief, to 20 μL of a stock solution of LecA and 
fluorescent ligand (final assay concentration 10 nM) in TBS/Ca were added 10 µL serial dilutions of 
test compounds in TBS/Ca in triplicates in black 384-well microtiter plates (Greiner Bio-One, 
Germany, cat no 781900). After addition of the reagents, the microtiter plates were centrifuged at 
800 rpm for 1 min at 23 °C and subsequently incubated for 4-6 h at r.t. in a humidity chamber on a 
rocking table. Fluorescence was measured on a PheraStar FS plate reader (BMG Labtech GmbH, 
Germany) with excitation filters at 485 nm and parallel and perpendicular emission filters at 535 
nm. The measured intensities were reduced by the values of only LecA in buffer. The fluorescence 
polarization data were calculated and analyzed with MARS Data Analysis Software (BMG Labtech 
GmbH, Germany) and fitted according to the four parameter variable slope model. Bottom and top 
plateaus were defined by the standard compounds included as controls in each assay (methyl α-D-
galactoside and phenyl β-D-galactoside, respectively) and the data was reanalyzed with these values 
fixed. A minimum of three independent measurements on three plates was performed for each 
inhibitor.
Mass spectrometry
All intact protein ESI-MS-measurements were performed on a Dionex Ultimate 3000 RSLC system 
using an Aeris Widepore XB-C8, 150 x 2.1 mm, 3.6 μm dp column (Phenomenex, USA). 
Separation of 0.5 μL sample was achieved by a linear gradient from (A) H2O + 0.1% HCOOH to 
(B) MeCN + 0.1% HCOOH at a flow rate of 300 μL/min and 45 °C. The gradient was initiated by a 
1.0 min isocratic step at 2% B, followed by an increase to 75% B in 10 min to end with a 3 min step 
at 75% B before reequilibration with initial conditions. UV spectra were recorded by a DAD in the 
range from 200 to 600 nm. The LC flow was split to 75 μL/min before entering the maXis 4G hr-
ToF mass spectrometer (Bruker Daltonics, Bremen, Germany) using the standard Bruker ESI 
source. In the source region, the temperature was set to 180 °C, the capillary voltage was 4000 V, 
the dry-gas flow was 6.0 L/min and the nebulizer was set to 1.1 bar. Mass spectra were acquired in 
positive ionization mode ranging from 600-1800 m/z at 2.5 Hz scan rate. Protein masses were 
deconvoluted by using the Maximum Entropy algorithm (Spectrum Square Associates, Inc.).
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All MALDI-ToF measurements were acquired on a Bruker ultrafleXtreme MALDI-ToF/ToF mass 
spectrometer (Bruker Daltonics, Germany) equipped with a smartbeam II solid state 1 kHz laser. In-
source decay (ISD) experiments for top-down sequencing were performed in positive ion reflectron 
mode ranging from 4000-9000 m/z. The acceleration voltage was set to 25.00 kV, extraction voltage 
to 22.55 kV, lens voltage was held at 7.5 kV and reflector voltage was set to 26.45 kV. The ISD 
spectra comprised 80000 accumulated laser shots (arbitrary laser power of 20%) and were 
externally calibrated using c-type fragment ions generated from intact ubiquitin. All ISD samples 
were prepared by pre-mixing sample solution (250 μM protein in H2O) and matrix solution (1,5-
diaminonaphthalene saturated in MeCN: H2O +  0.1% TFA (50:50)) in a ratio of 1:2 (v:v) and 
spotted 0.5 μL onto a ground steel target.
Crystallization and structure determination
LecA dissolved in water to 10 mg/mL was co-crystallized with 2 mM ligand 3 after incubation 
during one day at room temperature. Crystallization screening was performed using the vapor 
diffusion method. Sitting drops of 200 nl drops containing a 1/1 (v/v) mix of protein and reservoir 
solution at 20 °C were made using the robot of the HTXlab, Grenoble, France. Crystal clusters were 
obtained in five days from solution 6 from the PEGs-I (Qiagen): 25% peg 2KMME 0.1M sodium 
acetate pH 4.6. A broken part of the cluster was directly mounted in a cryoloop and flash-freezed in 
liquid nitrogen. Diffraction data were collected at 100 K at the European Synchrotron Radiation 
Facility (Grenoble, France) on BM30A-FIP using an ADSC Q315r detector. The data were 
processed using XDS.[53] All further computing was performed using the CCP4 suite.[54] Data 
quality statistics are summarized in Table S1. The structure was solved by molecular replacement 
using PHASER and the tetramer coordinates of PDB-ID 1OKO as search model.[55] This model was 
initially rebuild using ARP/WARP[56] and then the structure was refined with restrained maximum 
likelihood refinement using REFMAC 5.8 and local NCS restrains[57] iterated with manual 
rebuilding in Coot.[58] Five percent of the observations were set aside for cross-validation analysis, 
and hydrogen atoms were added in their riding positions and used for geometry and structure-factor 
calculations. Incorporation of the ligand was performed after inspection of the ARP/WARP 2Fo-
DFc weighted maps. Water molecules, introduced first with ARP/WARP and then automatically 
using Coot, were inspected manually. The model was validated with the wwPDB Validation server: 
http://wwpdb-validation.wwpdb.org. The coordinates were deposited in the Protein Data Bank 
under code 5MIH.
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Microbiology
Generation of fluorescent Pseudomonas aeruginosa strains
Bacterial cultures were grown in LB medium at 37 °C and 180 rpm. P. aeruginosa PAO1 wt 
(DSM19880) and P. aeruginosa PAO1 ∆lecA (source Bodo Philipp, University of Münster) were 
transformed with mCherry expressing plasmid pMP7605[59] by three parental mating using E. coli 
DH5α (source Rolf Müller lab) as donor strain and E. coli HB101 [RK 600] (source Bodo Philipp, 
University of Münster) as helper strain. Bacterial pre-cultures were inoculated from single colonies 
in 5 mL LB with appropriate antibiotics (30 µg/mL chloramphenicol for bacteria containing 
pRK600; 15 µg/mL gentamicin for for bacteria containing pMP7605) and grown at 37 °C and 180 
rpm overnight to stationary phase. For each mating, 100 µL pre-culture was combined and washed 
twice with pre-warmed LB medium. Strain mixtures were resuspended in 30 µL pre-warmed LB 
medium and spotted onto pre-warmed LB agarose plates and incubated overnight at 37 °C. After 24 
hours from each plate all growth was resuspended in 1 mL LB per plate. 100 µL of the bacterial 
suspension and 100 µL of a 1:10 dilution were plated on LB-gentamicin (120 µg/mL) agar plates 
and incubated at 37 °C for 24 hours. Successfully transformed bacteria were gentamicin-resistant 
and the colonies were identified by their pink color and restreaked.
Biofilm experiments
Bacterial pre-cultures of P. aeruginosa PAO1 w.t. pMP7605 or ∆lecA pMP7605 were inoculated 
from single colonies in 5 mL LB and grown at 37 °C and 180 rpm overnight to stationary phase. 
For the biofilm assay the bacterial pre-cultures were diluted to an OD600nm of 0.02 in fresh LB 
medium. 400 µL bacterial culture were transferred to each well of a 24-well imaging plate (cat no 
3231, zell-kontakt GmbH, Germany). Plates were incubated at 37 °C and shaking at 180 rpm for 20 
- 24 hours. 
FITC-labelled epoxide 17 was suspended in H2O/10% DMSO (0.57 mg in 680 µL), centrifuged and 
the supernatant was used in the staining experiments. Biofilms were stained for the presence of 
LecA by the addition of 44 µL FITC-labelled epoxide 17 to each well. After an incubation time of 
10 - 30 min at r.t., bacterial biofilms were directly visualized by measuring the fluorescence of the 
fluorescein-labeled LecA ligand and mCherry using a confocal laser scanning microscope (Leica 
TCS Sp8 CLSM). Fluorescein was excited with a 488-nm laser and mCherry at 561 nm.  Focal 
planes were acquired starting from the bottom of the plate (position 0) with an interplane distance 
(z-step size) of 2 μm using a 25× numerical-aperture water objective. Images were batch-processed 
using the ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2016.) for background correction and noise filter 
("remove outliers").
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